CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Cellectar Biosciences, Inc. - CLRB CFD

    2.60
    4.42%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.04
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 2.49
    Open* 2.43
    1-Year Change* 44.64%
    Day's Range* 2.43 - 2.6
    52 wk Range 1.25-3.15
    Average Volume (10 days) 201.46K
    Average Volume (3 months) 15.22M
    Market Cap 26.30M
    P/E Ratio -100.00K
    Shares Outstanding 12.29M
    Revenue N/A
    EPS -3.44
    Dividend (Yield %) N/A
    Beta 1.05
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 7, 2023 2.49 0.10 4.18% 2.39 2.54 2.35
    Dec 6, 2023 2.52 0.03 1.20% 2.49 2.57 2.41
    Dec 5, 2023 2.54 0.15 6.28% 2.39 2.58 2.39
    Dec 4, 2023 2.49 -0.02 -0.80% 2.51 2.54 2.39
    Dec 1, 2023 2.54 0.12 4.96% 2.42 2.54 2.38
    Nov 30, 2023 2.42 0.28 13.08% 2.14 2.47 2.14
    Nov 29, 2023 2.22 0.05 2.30% 2.17 2.26 2.12
    Nov 28, 2023 2.19 0.11 5.29% 2.08 2.22 2.08
    Nov 27, 2023 2.13 0.04 1.91% 2.09 2.16 2.06
    Nov 24, 2023 2.06 -0.04 -1.90% 2.10 2.17 2.06
    Nov 22, 2023 2.17 0.08 3.83% 2.09 2.20 2.05
    Nov 21, 2023 2.11 -0.03 -1.40% 2.14 2.19 2.10
    Nov 20, 2023 2.15 0.16 8.04% 1.99 2.21 1.99
    Nov 17, 2023 2.04 0.12 6.25% 1.92 2.08 1.92
    Nov 16, 2023 1.97 0.00 0.00% 1.97 1.99 1.87
    Nov 15, 2023 1.97 0.01 0.51% 1.96 2.03 1.94
    Nov 14, 2023 1.99 -0.01 -0.50% 2.00 2.07 1.96
    Nov 13, 2023 2.03 0.11 5.73% 1.92 2.06 1.86
    Nov 10, 2023 1.93 0.04 2.12% 1.89 1.96 1.85
    Nov 9, 2023 1.94 -0.10 -4.90% 2.04 2.09 1.87

    Cellectar Biosciences, Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Cellectar Biosciences Inc Earnings Release
    Q4 2023 Cellectar Biosciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 28.8138 24.1313 15.1051 14.1786 13.3308
    Selling/General/Admin. Expenses, Total 9.59417 6.54481 5.14967 5.18257 4.82007
    Research & Development 19.2196 17.5865 10.1407 8.99606 6.83523
    Unusual Expense (Income) 0 -0.18528 0 1.67546
    Operating Income -28.8138 -24.1313 -15.1051 -14.1786 -13.3308
    Interest Income (Expense), Net Non-Operating 0.15252 0.00228 0.0109 0.08571 0.09174
    Net Income Before Taxes -28.6612 -24.1224 -15.0942 -14.0929 -13.239
    Net Income After Taxes -28.6012 -24.1224 -15.0942 -14.0929 -13.239
    Net Income Before Extra. Items -28.6012 -24.1224 -15.0942 -14.0929 -13.239
    Net Income -28.6012 -24.1224 -15.0942 -14.0929 -13.239
    Income Available to Common Excl. Extra. Items -28.6012 -24.1224 -15.0942 -14.0929 -15.4808
    Income Available to Common Incl. Extra. Items -28.6012 -24.1224 -15.0942 -14.0929 -15.4808
    Diluted Net Income -28.6012 -24.1224 -15.0942 -14.0929 -15.4808
    Diluted Weighted Average Shares 7.05567 5.55157 1.98127 0.76751 0.2962
    Diluted EPS Excluding Extraordinary Items -4.05366 -4.34514 -7.61845 -18.3619 -52.2653
    Diluted Normalized EPS -4.05366 -4.34514 -7.71196 -18.3619 -46.6087
    Total Adjustments to Net Income 0 -2.2418
    Revenue 0
    Other, Net 0 0.00663
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 8.294 8.7053 7.42254 7.81549 7.43552
    Selling/General/Admin. Expenses, Total 1.98557 2.05121 1.96878 2.4353 2.93687
    Research & Development 6.30843 6.65409 5.45376 5.38019 4.49866
    Operating Income -8.294 -8.7053 -7.42254 -7.81549 -7.43552
    Interest Income (Expense), Net Non-Operating 0.07278 0.12403 0.14744 0.00416 0.00048
    Net Income Before Taxes -8.22122 -8.58127 -7.27509 -7.81132 -7.43504
    Net Income After Taxes -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
    Net Income Before Extra. Items -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
    Net Income -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
    Income Available to Common Excl. Extra. Items -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
    Income Available to Common Incl. Extra. Items -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
    Diluted Net Income -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
    Diluted Weighted Average Shares 11.2612 11.2612 9.89229 6.11012 6.11012
    Diluted EPS Excluding Extraordinary Items -0.73005 -0.76202 -0.72937 -1.27842 -1.21684
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.73005 -0.76202 -0.72937 -1.27842 -1.21684
    Unusual Expense (Income)
    Other, Net
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 20.5296 36.5715 57.9398 11.3857 13.9518
    Cash and Short Term Investments 19.8664 35.704 57.1654 10.6147 13.2556
    Cash & Equivalents 19.8664 35.704 57.1654 10.6147 13.2556
    Prepaid Expenses 0.66324 0.86749 0.77443 0.77095 0.64122
    Other Current Assets, Total 0 0.055
    Total Assets 21.5898 37.2018 58.6594 12.2508 15.0541
    Property/Plant/Equipment, Total - Net 0.97898 0.54914 0.63835 0.78392 0.54334
    Property/Plant/Equipment, Total - Gross 1.67151 1.09391 1.04202 1.09333
    Accumulated Depreciation, Total -0.69253 -0.54478 -0.40367 -0.30941
    Goodwill, Net 0
    Other Long Term Assets, Total 0.08121 0.08121 0.08121 0.08121 0.55891
    Total Current Liabilities 5.52929 3.99036 3.5631 2.76976 1.62212
    Payable/Accrued 1.63744 1.88091 0.7872 0.71987 1.54382
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.00221
    Other Current Liabilities, Total 0 0.07609
    Total Liabilities 6.08227 4.15666 3.86484 3.1914 1.79312
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Capital Lease Obligations 0
    Other Liabilities, Total 0.55298 0.16629 0.30174 0.42164 0.171
    Total Equity 15.5075 33.0452 54.7945 9.05941 13.261
    Redeemable Preferred Stock 1.38202 1.38202 20.0359 1.1482 2.52605
    Common Stock 0.00009 0.00061 0.00045 0.00009 0.00005
    Additional Paid-In Capital 193.624 182.56 161.534 119.592 108.323
    Retained Earnings (Accumulated Deficit) -179.499 -150.898 -126.775 -111.681 -97.5883
    Total Liabilities & Shareholders’ Equity 21.5898 37.2018 58.6594 12.2508 15.0541
    Total Common Shares Outstanding 9.38527 6.11013 4.54427 0.93867 0.47324
    Total Preferred Shares Outstanding 0.00011 0.00011 0.00173 0.00022 0
    Accounts Payable 2.558 1.415 1.429 1.278
    Accrued Expenses 1.33385 0.69445 1.3469 0.77189
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 20.1099 5.60965 13.8464 20.5296 18.7613
    Cash and Short Term Investments 18.9864 5.15297 12.6827 19.8664 17.7853
    Cash & Equivalents 18.9864 5.15297 12.6827 19.8664 17.7853
    Prepaid Expenses 1.12347 0.45668 1.16375 0.66324 0.97594
    Total Assets 21.5508 6.50917 14.8385 21.5898 19.3195
    Property/Plant/Equipment, Total - Net 1.41108 0.86973 0.92259 0.97898 0.47704
    Other Long Term Assets, Total 0.02978 0.02978 0.06943 0.08121 0.08121
    Total Current Liabilities 16.4708 6.44531 6.95565 5.52929 6.51524
    Payable/Accrued 7.81459 6.39167 6.90455 5.47844 6.36704
    Accrued Expenses 0.05626 0.05364 0.05111 0.05085 0.1482
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 16.9836 6.97617 7.504 6.08227 6.569
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.51275 0.53086 0.54834 0.55298 0.05377
    Total Equity 4.56716 -0.467 7.33446 15.5075 12.7505
    Redeemable Preferred Stock 19.302 1.38202 1.38202 1.38202 1.38202
    Common Stock 0.0001 0.0001 0.0001 0.00009 0.00006
    Additional Paid-In Capital 195.299 194.452 194.033 193.624 183.652
    Retained Earnings (Accumulated Deficit) -210.034 -196.302 -188.08 -179.499 -172.284
    Total Liabilities & Shareholders’ Equity 21.5508 6.50917 14.8385 21.5898 19.3195
    Total Common Shares Outstanding 9.91838 9.74051 9.74051 9.38527 6.11012
    Total Preferred Shares Outstanding 0.00011 0.00011 0.00011 0.00011 0.00011
    Other Current Liabilities, Total 8.6
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -28.6012 -24.1224 -15.0942 -14.0929 -13.239
    Cash From Operating Activities -25.2223 -22.5688 -13.9327 -11.6937 -11.4421
    Cash From Operating Activities 0.14844 0.14992 0.14145 0.1328 0.08227
    Non-Cash Items 1.54678 1.20485 0.34874 0.88035 2.28372
    Cash Interest Paid 0 0.00158 0.00088 0
    Changes in Working Capital 1.68374 0.19876 0.67124 1.38605 -0.56905
    Cash From Investing Activities -0.22597 -0.14136 -0.06235 -0.02454 -0.32999
    Capital Expenditures -0.22597 -0.14136 -0.06235 -0.02454 -0.38499
    Cash From Financing Activities 9.61066 1.2488 60.5457 9.02236 15.0213
    Financing Cash Flow Items 0 -0.00076
    Issuance (Retirement) of Stock, Net 9.61066 1.2488 60.3618 9.02457 15.0251
    Issuance (Retirement) of Debt, Net 0 0.184 -0.00221 -0.00304
    Net Change in Cash -15.8376 -21.4614 46.5507 -2.69589 3.2492
    Other Investing Cash Flow Items, Total 0 0.055
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -8.58127 -28.6012 -21.3862 -13.5748 -6.1398
    Cash From Operating Activities -7.18367 -25.2223 -17.8105 -10.7974 -5.03978
    Cash From Operating Activities 0.04256 0.14844 0.11028 0.07732 0.04342
    Non-Cash Items 0.42204 1.54678 1.16145 0.77068 0.32516
    Cash Interest Paid
    Changes in Working Capital 0.93301 1.68374 2.3039 1.92949 0.73143
    Cash From Financing Activities 0 9.61066 0 0 0
    Issuance (Retirement) of Stock, Net 0 9.61066 0 0 0
    Net Change in Cash -7.18367 -15.8376 -17.9186 -10.8984 -5.06985
    Cash From Investing Activities 0 -0.22597 -0.10812 -0.10105 -0.03007
    Capital Expenditures 0 -0.22597 -0.10812 -0.10105 -0.03007
    Issuance (Retirement) of Debt, Net
    Financing Cash Flow Items

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Cellectar Biosciences, Inc. Company profile

    About Cellectar Biosciences Inc

    Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. Through its Phospholipid drug conjugate (PDC) deliver platform the Company is focused on to develop PDCs that are designed to target cancer cells. The Company's pipeline consists of clinical and pre-clinical product candidates. Its lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells. PDC product candidates also include CLR 1900, 2000 and 12120 series of conjugated compounds, which is being researched independently and through partnerships. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis a pathway for treating cancers. CLR 2000 Series is a collaborative PDC program with Avicenna Oncology. CLR 12120 Series is a collaborative PDC program with Orano Med for the development of PDCs.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Cellectar Biosciences Inc revenues was not reported. Net loss increased 60% to $24.1M. Higher net loss reflects Reaserch and development increase of 74% to $17.5M (expense), General and administrative increase of 16% to $5.5M (expense), General and administrative increase from $395K to $1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.43.

    Equity composition

    Common Stock $.00153 Par, 03/11, 150M auth., 731,576 issd. Insiders own 47.57%. Preferred Stock $.00001 Par, 7K auth., Ser.C 204 issd. Sr E $0.00001 Par, 408.264045 issd., 04/11, 1-for-153 reverse split. 06/14, 1-for-20 Reverse stock split. 03/16 1-for-10 Reverse stock split.

    Industry: Pharmaceuticals (NEC)

    100 Campus Drive
    FLORHAM PARK
    NEW JERSEY 07932
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    XRP/USD

    0.68 Price
    +3.860% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading